Payment overview · 2025
General Payments
$1,150.55
69 reported records · 17 companies
Healthcare provider profile · identity verified
Darrell W Plumage, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PIERRE, SD · NPI 1013938844
Verified facts
What the public records show
CMS Open Payments records show Darrell W Plumage, MD received $1,150.55 in general payments during 2025 across 69 reported records.
PFIZER INC. accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $159.52 | 13.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $155.30 | 13.5% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $150.57 | 13.1% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $110.32 | 9.6% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$91.29 | 7.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.66 | 7.9% | 6 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $80.99 | 7.0% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $77.70 | 6.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.87 | 5.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.85 | 2.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.57 | 2.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.76 | 2.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.06 | 1.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.52 | 1.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.31 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.64 | 1.3% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $13.62 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,150.55 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $150.57 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $134.58 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $134.58 | 9 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $91.29 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $90.66 | 6 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $90.66 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $89.00 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $89.00 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $84.70 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $81.00 | 5 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $80.99 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $77.70 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $70.52 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $70.52 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $70.52 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.87 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.87 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.85 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.57 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $29.32 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.72 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 26 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 298 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 143 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 147 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
98 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
298 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
147 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
298 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1020 | 212 |
| Amlodipine Besylate | Amlodipine Besylate | 694 | 151 |
| Omeprazole | Omeprazole | 540 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 515 | 105 |
| Losartan Potassium | Losartan Potassium | 499 | 101 |
| Furosemide | Furosemide | 479 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 371 | 68 |
| Potassium Chloride | Potassium Chloride | 368 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 352 | 77 |
| Sertraline Hcl | Sertraline Hcl | 324 | 61 |
| Warfarin Sodium | Warfarin Sodium | 321 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 313 | 70 |
| Eliquis | Apixaban | 298 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 63 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 251 | 56 |
| Gabapentin | Gabapentin | 243 | 44 |
| Metformin Hcl | Metformin Hcl | 224 | 58 |
| Carvedilol | Carvedilol | 219 | 49 |
| Meloxicam | Meloxicam | 219 | 56 |
| Lisinopril | Lisinopril | 214 | 46 |
| Montelukast Sodium | Montelukast Sodium | 182 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 170 | 29 |
| Allopurinol | Allopurinol | 164 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 34 |
| Trazodone Hcl | Trazodone Hcl | 160 | 35 |
| Tramadol Hcl | Tramadol Hcl | 158 | 38 |
| Ozempic | Semaglutide | 147 | 17 |
| Jardiance | Empagliflozin | 143 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 30 |
| Alendronate Sodium | Alendronate Sodium | 138 | 32 |
| Valsartan | Valsartan | 126 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 125 | 15 |
| Famotidine | Famotidine | 113 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 16 |
| Myrbetriq | Mirabegron | 98 | 18 |
| Prednisone | Prednisone | 98 | 50 |
| Celecoxib | Celecoxib | 97 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 23 |
| Baclofen | Baclofen | 93 | 12 |
| Donepezil Hcl | Donepezil Hcl | 93 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 24 |
| Xarelto | Rivaroxaban | 89 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 44 |
| Cephalexin | Cephalexin | 87 | 40 |
| Simvastatin | Simvastatin | 86 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 82 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 82 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 81 | 12 |
| Mirtazapine | Mirtazapine | 76 | 23 |
| Glimepiride | Glimepiride | 70 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | suppressed |
| Bupropion Xl | Bupropion Hcl | 64 | 13 |
| Divalproex Sodium | Divalproex Sodium | 62 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 61 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 17 |
| Clonidine Hcl | Clonidine Hcl | 58 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 12 |
| Irbesartan | Irbesartan | 56 | 14 |
| Metformin Hcl Er | Metformin Hcl | 55 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | suppressed |
| Olanzapine | Olanzapine | 53 | suppressed |
| Mounjaro | Tirzepatide | 51 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 50 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 14 |
| Finasteride | Finasteride | 48 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Ondansetron Odt | Ondansetron | 46 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | suppressed |
| Latanoprost | Latanoprost | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 11 |
| Spironolactone | Spironolactone | 43 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 42 | 14 |
| Clozapine | Clozapine | 41 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Digoxin | Digoxin | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | 14 |
| Fentanyl | Fentanyl | 36 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Cefdinir | Cefdinir | 31 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 31 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 26 | 26 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 23 |
| Nuplazid | Pimavanserin Tartrate | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Admelog Solostar | Insulin Lispro | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Ingrezza | Valbenazine Tosylate | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Sulindac | Sulindac | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Cefadroxil | Cefadroxil | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,150.55 · 69 records | PFIZER INC. | ABRYSVO, CAMZYOS, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, ENFLONSIA, EVENITY, GARDASIL 9, INSPIRE, JARDIANCE, JOURNAVX, LEQVIO, M-M-R II, MINIMED 780G, MOUNJARO, NURTEC ODT, OPSUMIT, Ozempic, PREVNAR 20, PROLIA, QULIPTA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, UPTRAVI, VAXNEUVANCE, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error